Compare CXT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXT | BEAM |
|---|---|---|
| Founded | 1855 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1994 | 2019 |
| Metric | CXT | BEAM |
|---|---|---|
| Price | $39.32 | $32.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $73.00 | $50.75 |
| AVG Volume (30 Days) | 710.5K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $3,374,900,000.00 | $24,000.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.22 | $33.77 |
| P/E Ratio | $373.09 | ★ N/A |
| Revenue Growth | 6.13 | ★ 33.33 |
| 52 Week Low | $37.00 | $15.60 |
| 52 Week High | $69.00 | $36.44 |
| Indicator | CXT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 59.79 |
| Support Level | $37.00 | $25.85 |
| Resistance Level | $46.74 | $34.29 |
| Average True Range (ATR) | 1.83 | 1.85 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 22.46 | 72.25 |
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.